Cargando…

Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?

Background: Health-related quality of life (HRQoL) is a rapidly growing area of expertise and the most commonly used patient-reported outcome (PRO). The impact of cystic fibrosis (CF) on HRQoL is liable to be great, making CF patients ideal candidates for the application of HRQoL instruments. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Salek, M. Sam, Jones, S., Rezaie, M., Davies, C., Mills, R., Ketchell, R. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298894/
https://www.ncbi.nlm.nih.gov/pubmed/22416231
http://dx.doi.org/10.3389/fphar.2012.00038
_version_ 1782226053814550528
author Salek, M. Sam
Jones, S.
Rezaie, M.
Davies, C.
Mills, R.
Ketchell, R. I.
author_facet Salek, M. Sam
Jones, S.
Rezaie, M.
Davies, C.
Mills, R.
Ketchell, R. I.
author_sort Salek, M. Sam
collection PubMed
description Background: Health-related quality of life (HRQoL) is a rapidly growing area of expertise and the most commonly used patient-reported outcome (PRO). The impact of cystic fibrosis (CF) on HRQoL is liable to be great, making CF patients ideal candidates for the application of HRQoL instruments. The aims of this study were to assess the affect of CF on HRQoL, to ascertain the reliability and validity of the United Kingdom Sickness Impact Profile (UKSIP) and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL) in the adult CF population, and to examine their role in the management of patients. Methods: Seventy participants were recruited from the All Wales Adult Cystic Fibrosis Centre at Llandough Hospital, UK. There were two stages to the study: self-report of the UKSIP and CFQoL; and completion of the same two questionnaires 7–10 days later. Results: The areas of HRQoL most impaired by CF were employment and concerns regarding the future. The UKSIP and CFQoL showed high internal consistency (rα = 0.89–0.93) and test–retest reliability (r(s) = 0.57–0.94, p < 0.005) in the CF population. Validity was variable with the UKSIP showing discrimination across socio-demographic factors, whilst the CFQoL showed increased sensitivity to clinical variables. Many parameters influenced patient-reported HRQoL, with the greatest correlations seen with the Borg score (p < 0.005). The use of a HRQoL instrument in CF annual reviews is recommended to provide holistic patient care. The results of this study underpin the value of HRQoL as a patient-reported outcome measure in the management of adult CF.
format Online
Article
Text
id pubmed-3298894
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-32988942012-03-13 Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis? Salek, M. Sam Jones, S. Rezaie, M. Davies, C. Mills, R. Ketchell, R. I. Front Pharmacol Pharmacology Background: Health-related quality of life (HRQoL) is a rapidly growing area of expertise and the most commonly used patient-reported outcome (PRO). The impact of cystic fibrosis (CF) on HRQoL is liable to be great, making CF patients ideal candidates for the application of HRQoL instruments. The aims of this study were to assess the affect of CF on HRQoL, to ascertain the reliability and validity of the United Kingdom Sickness Impact Profile (UKSIP) and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL) in the adult CF population, and to examine their role in the management of patients. Methods: Seventy participants were recruited from the All Wales Adult Cystic Fibrosis Centre at Llandough Hospital, UK. There were two stages to the study: self-report of the UKSIP and CFQoL; and completion of the same two questionnaires 7–10 days later. Results: The areas of HRQoL most impaired by CF were employment and concerns regarding the future. The UKSIP and CFQoL showed high internal consistency (rα = 0.89–0.93) and test–retest reliability (r(s) = 0.57–0.94, p < 0.005) in the CF population. Validity was variable with the UKSIP showing discrimination across socio-demographic factors, whilst the CFQoL showed increased sensitivity to clinical variables. Many parameters influenced patient-reported HRQoL, with the greatest correlations seen with the Borg score (p < 0.005). The use of a HRQoL instrument in CF annual reviews is recommended to provide holistic patient care. The results of this study underpin the value of HRQoL as a patient-reported outcome measure in the management of adult CF. Frontiers Research Foundation 2012-03-12 /pmc/articles/PMC3298894/ /pubmed/22416231 http://dx.doi.org/10.3389/fphar.2012.00038 Text en Copyright © 2012 Salek, Jones, Rezaie, Davies, Mills and Ketchell. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
spellingShingle Pharmacology
Salek, M. Sam
Jones, S.
Rezaie, M.
Davies, C.
Mills, R.
Ketchell, R. I.
Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
title Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
title_full Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
title_fullStr Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
title_full_unstemmed Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
title_short Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
title_sort do patient-reported outcomes have a role in the management of patients with cystic fibrosis?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298894/
https://www.ncbi.nlm.nih.gov/pubmed/22416231
http://dx.doi.org/10.3389/fphar.2012.00038
work_keys_str_mv AT salekmsam dopatientreportedoutcomeshavearoleinthemanagementofpatientswithcysticfibrosis
AT joness dopatientreportedoutcomeshavearoleinthemanagementofpatientswithcysticfibrosis
AT rezaiem dopatientreportedoutcomeshavearoleinthemanagementofpatientswithcysticfibrosis
AT daviesc dopatientreportedoutcomeshavearoleinthemanagementofpatientswithcysticfibrosis
AT millsr dopatientreportedoutcomeshavearoleinthemanagementofpatientswithcysticfibrosis
AT ketchellri dopatientreportedoutcomeshavearoleinthemanagementofpatientswithcysticfibrosis